47 articles by Jonathan Gardner
-
Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says
June 14, 2019 -
Bluebird sets $1.8M price tag for blood-disease gene therapy
June 14, 2019 -
Savara lung disease trial misses, but execs vow to press on
June 13, 2019 -
FTC demands could mean months-long delay for Roche-Spark deal
June 12, 2019 -
Novo Nordisk goes for broke on semaglutide heart data
June 11, 2019 -
Trulicity heart data falls short for Lilly investors
June 10, 2019 -
Amicus widens UPenn gene therapy collaboration
May 29, 2019 -
BioMarin readies hemophilia gene therapy for FDA submission
May 28, 2019 -
Pay-for-delay deals disappearing, FTC says
May 24, 2019 -
Could Novartis' gene therapy have more than one price?
May 23, 2019 -
5 novel immuno-oncology targets to know before ASCO
May 22, 2019 -
No news is bad news for Tocagen
May 22, 2019 -
Array gets a win in colorectal cancer
May 21, 2019 -
Long-term heart data reassures for Medicines Co.
May 20, 2019 -
Medicare decides against tighter management of HIV drugs
May 17, 2019 -
Breast cancer survival data buoys Macrogenics and Puma
May 16, 2019 -
Cost-effectiveness agency clears Biogen's Spinraza for UK patients
May 15, 2019 -
Solid's gene therapy stumble makes Sarepta's lead clearer
May 14, 2019 -
Generics price-fixing lawsuit focuses on Teva's role as catalyst
May 13, 2019 -
Fibrogen confuses as it tries to explain blood-boosting drug data
May 10, 2019 -
Biopharma happily takes the tax cuts, but the jobs are harder to find
May 9, 2019 -
AstraZeneca's share dilution gamble on Daiichi drug pays off
May 8, 2019 -
Roche risdiplam data heats up SMA rivalry with Novartis
May 7, 2019 -
Novartis makes final Zolgensma pitch before FDA decision
May 6, 2019 -
Approval of $225,000-a-year tafamidis comes early for Pfizer
May 6, 2019